CPB204

CPB204 is a preclinical-stage biologic candidate developed by Alephoson for the treatment of retinal vascular disorders, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The asset is built upon Alephoson's proprietary Cell-Penetrating Biologics (CPB) platform, which employs cell-penetrating peptides to enable the delivery of large therapeutic proteins into the posterior segment of the eye. This technology is designed to overcome the limitations of current standard-of-care treatments, which typically require invasive intravitreal injections, by potentially allowing for non-invasive administration routes such as topical eye drops. While the specific molecular target of CPB204 has not been explicitly disclosed, the program targets indications characterized by pathological angiogenesis and vascular permeability.